Schonfeld Strategic Advisors LLC Boosts Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Schonfeld Strategic Advisors LLC increased its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 28.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,113,272 shares of the company’s stock after buying an additional 467,738 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Caribou Biosciences were worth $3,360,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of CRBU. Geode Capital Management LLC raised its stake in Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the period. Sei Investments Co. purchased a new stake in shares of Caribou Biosciences during the 4th quarter worth approximately $102,000. JPMorgan Chase & Co. raised its stake in Caribou Biosciences by 475.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock valued at $3,969,000 after purchasing an additional 2,062,563 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after acquiring an additional 26,467 shares during the last quarter. Finally, Barclays PLC grew its position in Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after acquiring an additional 71,463 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Analysts Set New Price Targets

CRBU has been the topic of a number of recent research reports. Bank of America decreased their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $9.33.

Caribou Biosciences Stock Performance

Shares of CRBU stock opened at $0.88 on Friday. The stock has a 50 day moving average price of $0.92 and a 200 day moving average price of $1.50. The firm has a market capitalization of $81.84 million, a P/E ratio of -0.53 and a beta of 2.36. Caribou Biosciences, Inc. has a 52-week low of $0.66 and a 52-week high of $3.93.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. As a group, sell-side analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.